| Name | Riociguat |
| Description | Riociguat (BAY 632521) is a stimulator of guanylate cyclase which causes relaxation of vascular smooth muscle and is used to treat severe pulmonary arterial hypertension. |
| In vitro | BAY 63-2521 (Riociguat) concentration-dependently stimulates the recombinant soluble guanylate cyclase (sGC) from 0.1 to 100 μM, resulting in a two-fold to 73-fold increase, through an NO-independent but haem-dependent mechanism. [1] Additionally, Riociguat impairs platelet function in isolated platelets, though it does not affect platelets in whole blood, nor does it directly influence the contractility and relaxation of cardiac myocytes. [2] [3] |
| In vivo | In a long-term study, Riociguat (10 mg/kg/d, orally) was found to partially mitigate pulmonary arterial hypertension, right heart hypertrophy, and structural remodeling of lung vasculature in hypoxic mice and monocrotaline (MCT)-injected rats. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 15 mg/mL (35.51 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Inhibitor | BAY-632521 | inhibit | Guanylate Cyclase | BAY632521 | Riociguat |
| Inhibitors Related | LY83583 | Lificiguat | Sinitrodil | Nelociguat | Nitroprusside disodium dihydrate | Vericiguat | ODQ | Methylene Blue | Methylene Blue trihydrate | Cinaciguat |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
